Terumo to Showcase BSD's MicroThermX® Microwave Ablation System at CIRSE – World's Largest Interventional Radiology Conference

Wed, 09/04/2013 - 9:15am
Business Wire

BSD Medical Corporation announced today that Terumo Europe NV, a wholly owned subsidiary of Terumo Corporation, will showcase BSD's MicroThermX ® Microwave Ablation System (MicroThermX) at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference. CIRSE, which will be held in Barcelona, Spain, on September 14-18, 2013, is the world's largest and most prestigious conference in the field of minimally invasive image-guided therapies. In preparation for CIRSE, Terumo is sponsoring focused training sessions for all Terumo sales representatives to ensure they are prepared to capitalize on MicroThermX sales during the conference. As part of the overall sales strategy for the conference, Terumo is placing MicroThermX systems with key physician opinion leaders throughout Europe. Terumo will also send MicroThermX promotional material to all conference attendees. Over 6,000 medical professionals from 85 countries attend CIRSE, reflecting the global impact of the rapidly expanding field of interventional radiology.

Terumo is also sponsoring a symposium at CIRSE highlighting the advantages of the MicroThermX. The symposium will feature three presentations focused solely on MicroThermX. "Microwave for lung tumour ablation: potential advantages compared with radiofrequency ablation and clinical settings" will be presented by Professor Philippe Pereira. "Microwave for liver tumour ablation: potential advantages compared with radiofrequency ablation and clinical settings" will be presented by Dr. Laura Crocetti. "Lessons from Microwave ablation with MicroThermX™: why, when, where and how" will be presented by Dr. Damian Dupuy. Professor Pereira and Drs. Crocetti and Dupuy are leading experts in the field of interventional oncology.

"We are excited to announce that Terumo will focus on the MicroThermX at CIRSE, the largest interventional oncology conference in the world. Terumo's aggressive marketing strategy should allow them to capture a significant share of the rapidly growing interventional oncology market," said Harold Wolcott, BSD President and CEO. "BSD’s exclusive distribution agreement with Terumo Europe NV for 100 countries represents one of the most significant milestones in our corporate history. The potential market size for thermal ablation in these countries is estimated to be in excess of $1 billion in annual sales."


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.